Literature DB >> 9032518

Physiology and pathophysiology of pleural fluid turnover.

G Miserocchi1.   

Abstract

The pleural space contains a tiny amount (approximately 0.3 mL.kg-1) of hypooncotic fluid (approximately 1 g.dL-1 protein). Pleural fluid turnover is estimated to be approximately 0.15 mL.kg-1.h-1. Pleural fluid is produced at parietal pleural level, mainly in the less dependent regions of the cavity. Reabsorption is accomplished by parietal pleural lymphatics in the most dependent part of the cavity, on the diaphragmatic surface and in the mediastinal regions. The flow rate in pleural lymphatics can increase in response to an increase in pleural fluid filtration, acting as a negative feedback mechanism to control pleural liquid volume. Such control is very efficient, as a 10 fold increase in filtration rate would only result in a 15% increase in pleural liquid volume. When filtration exceeds maximum pleural lymphatic flow, pleural effusion occurs: as an estimate, in man, maximum pleural lymph flow could attain 30 mL.h-1, equivalent to approximately 700 mL.day-1 (approximately 40% of overall lymph flow). Under physiological conditions, the lung interstitium and the pleural space behave as functionally independent compartments, due to the low water and solute permeability of the visceral pleura. Pleural fluid circulates in the pleural cavity and intrapleural fluid dynamics may be represented by a porous flow model. Lubrication between lung and chest wall is assured by oligolamellar surfactant molecules stratified on mesothelial cells of the opposing pleurae. These molecules carry a charge of similar sign and, therefore, repulse each other, assuring a graphite-like lubrication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032518     DOI: 10.1183/09031936.97.10010219

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  50 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  BTS guidelines for the management of pleural infection in children.

Authors:  I M Balfour-Lynn; E Abrahamson; G Cohen; J Hartley; S King; D Parikh; D Spencer; A H Thomson; D Urquhart
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

Review 3.  Antenatal modes of surfactant administration for RDS prevention: a review.

Authors:  Adam Ostrzenski; Bartholomew Radolinski; Katarzyna M Ostrzenska
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

4.  Electrolyte and Fluid Transport in Mesothelial Cells.

Authors:  Hong-Long Ji; Hong-Guang Nie
Journal:  J Epithel Biol Pharmacol       Date:  2008

Review 5.  Interpreting pleural fluid results .

Authors:  Rachel M Mercer; John P Corcoran; Jose M Porcel; Najib M Rahman; Ioannis Psallidas
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

Review 6.  Biochemical Analysis of Pleural Fluid and Ascites.

Authors:  Sa Paul Chubb; Robin A Williams
Journal:  Clin Biochem Rev       Date:  2018-05

7.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 8.  Pneumonia and empyema: causal, casual or unknown.

Authors:  Lindsay McCauley; Nathan Dean
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 9.  Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma.

Authors:  Ken Donaldson; Fiona A Murphy; Rodger Duffin; Craig A Poland
Journal:  Part Fibre Toxicol       Date:  2010-03-22       Impact factor: 9.400

10.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.